Radiopharm Theranostics company information, Employees & Contact Information

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs GlobeNewswire

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update Yahoo Finance

Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors Investing News Network

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases Investing News Network

Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis Investing News Network

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial GlobeNewswire

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board Yahoo Finance

Radiopharm Theranostics Receives IND approval from US FDA GlobeNewswire

Radiopharm Theranostics and Cyclotek Sign Clinical Supply GlobeNewswire

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb GlobeNewswire

Radiopharm Theranostics Doses First Patient in Phase 1 GlobeNewswire

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC) GlobeNewswire

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia GlobeNewswire

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement GlobeNewswire

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial GlobeNewswire

Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan GlobeNewswire

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177 GlobeNewswire

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases GlobeNewswire

AtomVie Global Radiopharma and Radiopharm Theranostics Partner to Develop and Manufacture 177Lu-BetaBart Radioantibody for Treatment of Multiple Solid Tumors PR Newswire

Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types Investing News Network

Radiopharm Theranostics Receives FDA IND Approval for Phase 2b Imaging Trial in Brain Metastases Investing News Network

Radiopharm Receives Strategic Investment for up to A$18 million GlobeNewswire

Investor Webinar – 3pm AEST Tuesday 2 July Investing News Network

Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals GlobeNewswire

MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS PR Newswire